The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

• श्रेणी